Outcomes For Patients In The Pembrolizumab Plus Axitinib Arm With Advanced Renal Cell Carcinoma (Rcc) Who Completed Two Years Of Treatment In The Phase Iii Keynote-426 Study.
JOURNAL OF CLINICAL ONCOLOGY（2021）
摘要
327Background: In the randomized, open-label, phase III KEYNOTE-426 study (NCT02853331), pembrolizumab + axitinib significantly improved overall survival (OS), progression-free survival (PFS), and ...
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要